Jason Gotlib, MD, MS is Professor of Medicine in the Division of Hematology at the Stanford University School of Medicine / Stanford Cancer Institute. Dr. Gotlib’s medical school, residency, and fellowship training was undertaken at Stanford, where he also earned a Master’s degree in clinical epidemiology. He was the recipient of the National Institutes of Health K23 Career Development Award. He was Director of the Stanford Hematology Fellowship Training Program from 2011-2017 and has been a six time-recipient of the Stanford Division of Hematology’s teaching award.
Dr. Gotlib's research focus is clinical trial and translational evaluation of novel therapies for myeloproliferative neoplasms (MPNs) such as JAK inhibitors for myelofibrosis. He has authored more than 200 reviews, chapters, and research articles that have been published in journals such as Blood, Journal of Clinical Oncology, Leukemia, and The New England Journal of Medicine. He has also been Associate Editor or has served on the Editorial Board of several hematology journals.
Dr. Gotlib is a member of the National Comprehensive Cancer Network (NCCN) Guidelines Committee for Chronic Myeloid Leukemia, Vice-Chair of the NCCN Guidelines Committee on Myeloproliferative Neoplasms, and Chaired the recent development of NCCN guidelines for Systemic Mastocyosis (SM). Dr. Gotlib led the development of midostaurin for patients with advanced SM, which was approved by the FDA in 2017. Dr. Gotlib is a founding member of the newly created American Initiative on Mast Cell Diseases (AIM), a Pan-American Network whose mission is to advance the research, education, and treatment of mast cell disorders. In addition to serving as Editor-in-Chief of ASH’s The Hematologist, he will be the Educational Co-Chair for the upcoming 2019 annual ASH meeting.